Preclinical Data Demonstrate Potential of Prevail’s AAV Gene Therapy Approach to Slow or Halt Progression in Multiple Neurodegenerative Diseases
Company Provides Design Overview for Planned Phase 1/2 PR001 PROVIDE and PR006 PROCLAIM Clinical TrialsNEW YORK, April 29, 2020 (GLOBE NEWSWIRE) — Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced two upcoming oral presentations and two poster presentations at the virtual 2020 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. These data underscore the robust preclinical evidence in support of Prevail’s AAV-based gene therapy approach, and highlight the company’s strategy to validate these data in multiple ongoing or planned clinical trials.“Patients living with neurodegenerative diseases are in urgent need of novel therapies with the potential to slow or stop the course of their disease,” said Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail. “Our gene therapy candidates have the potential to improve outcomes for patients with genetically defined forms of Parkinson’s disease, frontotemporal dementia and neuronopathic Gaucher disease.”PR001Prevail will highlight the design of the planned PROVIDE Phase 1/2 trial for the treatment of Type 2 neuronopathic Gaucher disease (nGD) patients and preclinical data demonstrating the impact of PR001 treatment on key disease biomarkers and functional parameters. These data provide the basis for the company’s clinical programs in nGD and Parkinson’s disease with GBA1 mutations (PD-GBA).Poster title: Design of a Phase 1/2 Study to Evaluate the Safety and Efficacy of an AAV9-Based Gene Therapy in Infants with Type 2 Gaucher Disease (PROVIDE Trial)
Session title: AAV Vectors – Clinical Studies
Session date and time: Wednesday, May 13th, 5:30 p.m.-6:30 p.m. ETPresentation title: PR001 Gene Therapy Increased GCase Activity and Ameliorated GBA1-Associated Disease Phenotypes
Session title: AAV Vectors Preclinical and Proof-of-Concept Studies in Systemic Diseases
Presentation date and time: Thursday, May 14th 3:45 p.m.-4:00 p.m. ET
Presenter: Patty Sheehan, Ph.D., Senior Scientist, Prevail TherapeuticsPR006Poster title: Proposed Patient Population and Outcome Measures for a First in Human Study of PR006, an AAV9-Based Gene Therapy, for Fronto-Temporal Dementia Patients with Pathogenic GRN Mutations
Session title: AAV Vectors – Clinical Studies
Session date and time: Wednesday, May 13th, 5:30 p.m.-6:30 p.m. ETPresentation title: PR006, an AAV Gene Therapy Vector Expressing Progranulin, Improved FTD-GRN Phenotypes In Vitro and In Vivo
Session title: AAV Vectors Preclinical and Proof-of-Concept Studies in CNS Disorders
Presentation date and time: Friday, May 15th 10:15 a.m.-10:30 a.m. ET
Presenter: Laura D. Heckman, Ph.D., Director, Preclinical Development, Prevail TherapeuticsAbout Prevail Therapeutics
Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company is developing PR001 for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease; PR006 for patients with frontotemporal dementia with GRN mutations (FTD-GRN); and PR004 for patients with certain synucleinopathies.Prevail was founded by Dr. Asa Abeliovich in 2017, through a collaborative effort with The Silverstein Foundation for Parkinson’s with GBA and OrbiMed, and is headquartered in New York, NY.Media Contact:
Mary Carmichael
Ten Bridge Communications
[email protected]
617-413-3543Investor Contact:
[email protected]
Bay Street News
